These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 10438348)

  • 1. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era.
    Dworkin MS; Wan PC; Hanson DL; Jones JL
    J Infect Dis; 1999 Sep; 180(3):621-5. PubMed ID: 10438348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
    Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH;
    Clin Infect Dis; 2009 May; 48(10):1459-66. PubMed ID: 19348592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
    Thiessard F; Morlat P; Marimoutou C; Labouyrie E; Ragnaud JM; Pellegrin JL; Dupon M; Dabis F
    Cancer; 2000 Apr; 88(7):1696-702. PubMed ID: 10738229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
    Hoffmann C; Chow KU; Wolf E; Faetkenheuer G; Stellbrink HJ; van Lunzen J; Jaeger H; Stoehr A; Plettenberg A; Wasmuth JC; Rockstroh J; Mosthaf F; Horst HA; Brodt HR
    Br J Haematol; 2004 May; 125(4):455-62. PubMed ID: 15142115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study.
    Salzberger B; Rockstroh J; Wieland U; Franzen C; Schwenk A; Jütte A; Hegener P; Cornely O; Mörchen C; Gaensicke T; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Nov; 4(11):449-55. PubMed ID: 10585299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
    Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
    J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection: the clinical, neuroimaging, virological and evolutive characteristics in 35 patients].
    Asensi V; Cartón JA; Maradona JA; Oña M; Melón S; Martín-Roces ER; Asensi JM; Arribas JM
    Med Clin (Barc); 1999 Sep; 113(6):210-4. PubMed ID: 10472609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression.
    Dronda F; Moreno S; Moreno A; Casado JL; Pérez-Elías MJ; Antela A
    Clin Infect Dis; 2002 Oct; 35(8):1005-9. PubMed ID: 12355389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
    Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
    AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends of AIDS in Guadeloupe (French West Indies) a longitudinal survey from 1988 to 1997.
    Deloumeaux J; Foucan L; Sow-Goerger MT; Contamin B; Strobel M
    West Indian Med J; 2000 Jun; 49(2):148-53. PubMed ID: 10948855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients.
    Casado JL; Sabido R; Perez-Elías MJ; Antela A; Oliva J; Dronda F; Mejía B; Fortún J
    Antivir Ther; 1999; 4(3):157-61. PubMed ID: 12731755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy.
    Bakanda C; Birungi J; Mwesigwa R; Ford N; Cooper CL; Au-Yeung C; Chan K; Nachega JB; Wood E; Hogg RS; Dybul M; Mills EJ
    AIDS; 2011 Mar; 25(5):701-5. PubMed ID: 21160412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.